
Angeles Alvarez Secord
Professor of Obstetrics and GynecologyOverview
My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.
Positions
Professor of Obstetrics and Gynecology in the School of Medicine
2013 School of Medicine
Member of the Duke Cancer Institute in the School of Medicine
1994 School of Medicine
Education
M.D., University of Washington 1994
1994 University of Washington
Resident, Duke University, Obstetrics & Gynecology 1994 - 1998
1998 Duke University
Gynecologic Oncology Fellowship, Duke University, School of Medicine, OBSTETRICS & GYNECOLOGY 1998 - 2001
2001 Duke University, School of Medicine
Clinical Trials
NRG-CC008: Ovarian Cancer
NRG-GY025 Endometrial Cancer
NRG-GY026: Stage 1-IV Endometrial Serous Carcinoma or Carcinosarcoma
GOG-3078 Immunogen IMGN853-0421 (Ovarian and Fallopian Tube Cancers)
GOG-3083 XPORT-EC-042 SELINEXOR IN MAINTENANCE THERAPY FOR ADVANCED ENDOMETRIAL CANCER
ComboMATCH-EAY191-N5 (HER2-Positive Cancers)
GOG-3095 MK-2870-005 MK-2870 Monotherapy Vs. Physician's Choice in Endometrial Cancer
Biobanking for OVCA (Ovarian Cancer)
Endometrial Cancer Consortium
AFT-50 EndoMAP Targeted Agents and/or Immunotherapy with Atezolizumab for Endometrial Cancer
GOG-3096 DS6000-109 (Ovarian, Primary Peritoneal, and Fallopian Tube Cancers)
EAY191-N4 ComboMATCH (Ovarian and Endometrial Cancers)
GOG-3101 MK-2870-020 for cervical cancer
GOG-3107 RAINFOL Rinatabart versus Investigator's Choice (Ovarian Cancer)
GY036 for stage 3/4 gynecologic cancers with pathogenic BRCA 1/2 mutation or HR deficiency
Publications, Grants & Awards
- Grants (66)
- Academics Articles (306)
- Conference Pages (135)
- Book Sections (2)
DCI Centers, Cancer Types & Labs
Offices & Contact
Durham, NC
27710
Durham, NC
27710